Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
Sapna Pradyuman Patel
No relevant relationships to disclose
Wen-Jen Hwu
No relevant relationships to disclose
Kevin B. Kim
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Nicholas E. Papadopoulos
No relevant relationships to disclose
Patrick Hwu
No relevant relationships to disclose
Laszlo George Radvanyi
No relevant relationships to disclose
Sandy Mahoney
No relevant relationships to disclose
Tawania L Deburr
No relevant relationships to disclose
Ping Liu
No relevant relationships to disclose
Agop Y. Bedikian
Research Funding - Bristol-Myers Squibb